Binatta

LEAFLET INCLUDED IN THE PACKAGING

Leaflet included in the packaging: patient information

BINATTA, 25 mg, prolonged-release tablets

BINATTA, 50 mg, prolonged-release tablets

BINATTA, 100 mg, prolonged-release tablets

BINATTA, 150 mg, prolonged-release tablets

BINATTA, 200 mg, prolonged-release tablets

BINATTA, 250 mg, prolonged-release tablets

Tapentadol

Read the leaflet carefully before taking the medicine, as it contains important information for the patient.

• Keep this leaflet, you may need to read it again.
• In case of any doubts, consult a doctor or pharmacist.
• This medicine has been prescribed to you by a doctor and should not be given to others. It may harm them, even if their symptoms are the same as yours.
• If the patient experiences any side effects, including any not listed in this leaflet, they should inform their doctor, pharmacist, or nurse. See section 4.

Table of contents of the leaflet

• 1. What is BINATTA and what is it used for
• 2. Important information before taking BINATTA
• 3. How to take BINATTA
• 4. Possible side effects
• 5. How to store BINATTA
• 6. Contents of the pack and other information

1. What is BINATTA and what is it used for

Tapentadol, the active substance of BINATTA, is a strong pain reliever belonging to the opioid group. BINATTA is indicated for the treatment of severe chronic pain in adults, where only opioid pain relievers can provide adequate treatment.

2. Important information before taking BINATTA

When not to take BINATTA:

• if the patient is allergic to tapentadol or any of the other ingredients of this medicine (listed in section 6),
• in patients with asthma or dangerously slow and shallow breathing (respiratory depression, increased carbon dioxide levels in the blood),
• in patients with intestinal obstruction,
• in case of acute alcohol poisoning, sleeping pills, painkillers, or other psychotropic drugs (mood and emotion-affecting drugs) (see "BINATTA and other medicines").

Warnings and precautions

Before starting treatment with BINATTA, discuss the following with your doctor or pharmacist:

• in case of slow or shallow breathing,
• in case of increased intracranial pressure or impaired consciousness up to coma,
• in patients after head injury or with brain tumors,
• in patients with liver or kidney disease (see "How to take BINATTA"),
• in patients with pancreatic or biliary tract diseases, including pancreatitis,
• in patients taking mixed agonist-antagonist opioid receptor drugs (e.g., pentazocine, nalbuphine) or partial opioid receptor agonists (e.g., buprenorphine),
• in patients with a history of seizures or taking other medications that increase the risk of seizures and may increase the risk of attacks,
• in case of a family history of substance abuse or dependence (addiction),
• in patients who smoke tobacco,
• in patients who have ever had mood problems (depression, anxiety disorders, or personality disorders) or have been treated by a psychiatrist for other mental illnesses.

This medicine contains tapentadol, which is an opioid. Repeated use of opioid pain relievers can lead to decreased efficacy (tolerance) and may cause dependence and abuse, which can result in life-threatening overdose. If there is concern about dependence on BINATTA, consult a doctor. Taking the medicine (even at therapeutic doses) can lead to physical dependence, which may result in withdrawal symptoms and recurrence of problems if treatment is suddenly stopped.
BINATTA may cause physical and psychological dependence. If there is a tendency to abuse medications or addiction, treatment should be short-term and under close medical supervision.
Sleep apnea
BINATTA may cause sleep apnea, such as sleep apnea (pauses in breathing during sleep) and hypoxemia (low oxygen levels in the blood). Symptoms may include pauses in breathing during sleep, waking up at night due to shortness of breath, difficulty maintaining sleep continuity, or excessive daytime sleepiness. If these symptoms are observed, consult a doctor. The doctor may consider reducing the dose of the medicine.

BINATTA and other medicines

Tell your doctor or pharmacist about all medicines you are taking, have recently taken, or plan to take.

• The risk of side effects increases if you take medicines that can cause seizures (epileptic fits), such as antidepressants or antipsychotics. The risk of an attack may increase if you take BINATTA at the same time. Your doctor will inform you whether taking BINATTA is suitable for you.
• Taking BINATTA and sedatives, such as benzodiazepines or related drugs (some sleeping pills or tranquilizers, e.g., barbiturates) or painkillers, such as opioids, morphine, and codeine (also as a cough medicine), antipsychotics, antihistamines, alcohol, increases the risk of drowsiness, breathing difficulties (respiratory depression), coma, and can be life-threatening. Therefore, taking such medicines together should only be considered when other treatment options are not possible. However, if your doctor prescribes BINATTA in combination with sedatives, they should limit the dose and duration of concomitant treatment with such medicines. Concomitant use of opioids and medications used to treat epilepsy, neuralgia, or anxiety disorders (gabapentin and pregabalin) increases the risk of opioid overdose, respiratory depression, and can be life-threatening. Inform your doctor about taking gabapentin, pregabalin, or sedatives and strictly follow their instructions. It is worth informing friends or relatives about the possibility of the above-mentioned symptoms and consulting a doctor if they occur.

Opioid and epilepsy or anxiety disorder medications can increase the risk of opioid overdose, respiratory depression, and can be life-threatening. Inform your doctor about taking gabapentin, pregabalin, or sedatives and strictly follow their instructions.

• If you are taking medicines that affect serotonin levels (e.g., some antidepressants), consult your doctor before taking BINATTA, due to the possibility of "serotonin syndrome". Serotonin syndrome is rare but can be life-threatening. Its symptoms include: uncontrolled, rhythmic muscle contractions, including those that control eye movements, agitation, excessive sweating, trembling, excessive reflexes, including increased muscle tension and body temperature above 38°C. Your doctor can provide more information on this.
• The concomitant use of BINATTA with opioid mixed agonist/antagonist receptor drugs (e.g., pentazocine, nalbuphine) or partial agonists (e.g., buprenorphine) has not been studied. It is possible that BINATTA may not work properly if taken with medicines from the above groups. Immediately inform your doctor if you are taking any of the above medicines.
• Concomitant use of BINATTA with strong inhibitors or inducers (e.g., rifampicin, phenobarbital, St. John's Wort) of certain enzymes necessary for the elimination of tapentadol from the body may affect the action of tapentadol or cause side effects, especially when starting or stopping their administration. Tell your doctor about all medicines you are currently taking.
• BINATTA should not be taken with MAO inhibitors (medicines used to treat depression). Tell your doctor if you have taken these medicines in the last 14 days.

BINATTA with food, drink, and alcohol

Do not drink alcohol while taking BINATTA, as some side effects, such as drowsiness, may worsen. The medicine can be taken with or without food.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a baby, consult your doctor or pharmacist before taking this medicine.
Do not take BINATTA:

• during pregnancy, unless your doctor decides to prescribe it. Long-term use of tapentadol during pregnancy may cause withdrawal symptoms in newborns, which can be life-threatening if not recognized and treated by a doctor;
• while breastfeeding, as the medicine may be excreted in breast milk.

It is not recommended to take BINATTA:

• during childbirth, as it may cause dangerous respiratory depression in the newborn.

Driving and using machines

BINATTA may cause drowsiness, dizziness, blurred vision, and affect reaction time. These symptoms may occur especially at the beginning of treatment with BINATTA, after a dose change prescribed by your doctor, or when taking alcohol or sedatives. Ask your doctor if you can drive or operate machinery after taking BINATTA.

3. How to take BINATTA

Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.
Dosage should be adjusted according to the severity of pain and individual patient sensitivity to pain.
As a rule, the smallest effective dose should be used.

Adults

Typically, the initial dose is 50 mg, taken twice a day, approximately every 12 hours.
Total daily doses of BINATTA greater than 500 mg of tapentadol are not recommended.
Your doctor may prescribe a different, more suitable dose or interval between doses if necessary. If you feel that the effect of the medicine is too strong or too weak, consult your doctor or pharmacist.

Elderly patients

Dose adjustment is usually not necessary in elderly patients (over 65 years). Tapentadol elimination may be prolonged in this age group, and your doctor may prescribe a different dosing schedule.

Patients with impaired liver or kidney function

Patients with severe liver impairment should not take this medicine. In case of moderate liver impairment, your doctor will prescribe a different dosing schedule. Patients with mild liver impairment do not require dose adjustment.
Patients with severe kidney impairment should not take this medicine. In case of mild or moderate kidney impairment, dose adjustment is not required.

Use in children and adolescents

BINATTA is not recommended for use in children and adolescents under 18 years of age.

How to take BINATTA

BINATTA should be taken orally.
Swallow the tablet with a sufficient amount of liquid. The tablets should not be chewed or crushed

• this can lead to overdose due to rapid release of the medicine in the body. The medicine can be taken with or without food.

The tablet can be divided into equal doses.
The empty tablet shell may not be completely digested and may be present in the stool. Do not worry, as the medicine (active substance) has already been absorbed by the body, and only the tablet shell is present in the stool.

Instructions for opening the blister pack

This medicine is packaged in child-resistant, perforated blister packs, divided into single doses. Tablets cannot be pushed through the blister pack. Open the blister packs according to the following instructions:

• 1. Tear off a single dose along the perforated line of the blister pack.

• 2. The area where the lines intersect is not secured.

• 3. Pull the unsecured part to tear off the top protective layer.

Duration of treatment with BINATTA

Do not take the tablets for longer than prescribed by your doctor.

Taking a higher dose of BINATTA than recommended

After taking very high doses, the following symptoms may occur:

• pupils constricted to the size of a pinhead,
• vomiting,
• low blood pressure,
• rapid heartbeat,
• collapse, impaired consciousness, or coma (deep state of unconsciousness),
• seizures,
• dangerously slow or shallow breathing or respiratory arrest. In such cases, consult a doctor immediately!

Missing a dose of BINATTA

If you miss a dose, pain symptoms will likely return. Do not take a double dose to make up for the missed dose. Return to your previous dosing schedule.

Stopping treatment with BINATTA

If you stop or discontinue treatment with BINATTA before completing the treatment, pain symptoms will likely return. Consult your doctor before stopping the medicine.
As a rule, no side effects are observed after stopping the medicine, although in rare cases, patients who have taken the medicine for some time and stop it abruptly may experience general malaise.
The following symptoms may occur:

• restlessness, tearfulness, runny nose, yawning, sweating, chills, muscle pain, and dilated pupils,
• irritability, anxiety, back pain, joint pain, weakness, abdominal cramps, insomnia, nausea, loss of appetite, vomiting, diarrhea, increased blood pressure, respiratory rate, and heart rate. If you experience any of these symptoms after stopping treatment, consult your doctor immediately. Do not stop taking BINATTA abruptly, unless your doctor advises you to do so. Your doctor will inform you how to stop taking the medicine. Stopping the medicine may involve gradually reducing the dose.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, BINATTA can cause side effects, although not everybody gets them.

Important side effects or symptoms to watch out for and what to do if they occur:

• This medicine may cause allergic reactions. Symptoms may include wheezing, difficulty breathing, swelling of the eyelids, face, or lips, rash, or itching, especially affecting the whole body.
• Another serious side effect is excessive slowing and shallowing of breathing. This occurs most often in elderly and frail patients.

If any of these important side effects affect you, consult your doctor immediately.

Other side effects that may occur:

Very common(may affect more than 1 in 10 people)

• nausea, constipation,
• dizziness, drowsiness, headache.

Common(may affect up to 1 in 10 people)

• loss of appetite, anxiety, depressive mood, sleep disorders, nervousness, restlessness, concentration disorders,
• tremors, muscle spasms,
• flushing,
• shortness of breath,
• vomiting, diarrhea, indigestion,
• itching, excessive sweating, rash,
• feeling weak, fatigue, feeling of temperature change, dryness of mucous membranes, water retention (edema).

Uncommon(may affect up to 1 in 100 people)

• allergic reactions to the medicine (including skin swelling, hives, and in severe cases, difficulty breathing, low blood pressure, collapse, or shock),
• weight loss,
• disorientation, confusion, agitation (excitement), perception disorders, unusual dreams, euphoric mood, decreased level of consciousness, memory impairment, mental disorders,
• fainting, excessive sedation, balance disorders, speech disorders, tingling, abnormal skin sensations (e.g., burning, prickling),
• vision disorders,
• rapid heartbeat, slow heartbeat, palpitations, decreased blood pressure,
• abdominal discomfort,
• hives,
• urination disorders, frequent urination,
• sexual dysfunction,
• withdrawal syndrome (see "Stopping treatment with BINATTA"), feeling of abnormality, irritability.

Rare(may affect up to 1 in 1000 people)

• dependence on the medicine, thinking disorders, seizures, feeling of impending fainting, coordination disorders,
• dangerously slow or shallow breathing (respiratory depression),
• delayed gastric emptying,
• feeling of intoxication, feeling of relaxation.

Frequency not known(cannot be estimated from available data)

• delirium.

Generally, the risk of suicidal thoughts and behaviors is higher in patients with chronic pain. Additionally, medicines used to treat depression (which affect the neurotransmitter system in the brain) may increase this risk, especially at the beginning of treatment. Although tapentadol also affects neurotransmitters, data from human use have not provided evidence of an increased risk.

Reporting side effects

If you experience any side effects, including any not listed in this leaflet, tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help gather more information on the safety of this medicine.

5. How to store BINATTA

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and blister pack after EXP.
The expiry date refers to the last day of the month stated.
There are no special precautions for storing the medicine.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the pack and other information

What BINATTA contains

• The active substance of BINATTA is tapentadol.

BINATTA, 25 mg, prolonged-release tablets
Each prolonged-release tablet contains 25 mg of tapentadol (as phosphate).
BINATTA, 50 mg, prolonged-release tablets
Each prolonged-release tablet contains 50 mg of tapentadol (as phosphate).
BINATTA, 100 mg, prolonged-release tablets
Each prolonged-release tablet contains 100 mg of tapentadol (as phosphate).
BINATTA, 150 mg, prolonged-release tablets
Each prolonged-release tablet contains 150 mg of tapentadol (as phosphate).
BINATTA, 200 mg, prolonged-release tablets
Each prolonged-release tablet contains 200 mg of tapentadol (as phosphate).
BINATTA, 250 mg, prolonged-release tablets
Each prolonged-release tablet contains 250 mg of tapentadol (as phosphate).

• Other ingredients are: Tablet core:microcrystalline cellulose (E 460); hypromellose (E 464); colloidal anhydrous silica (E 551); magnesium stearate. Tablet coating:hypromellose (E 464); glycerol (E 422); talc (E 553b); microcrystalline cellulose (E 460); titanium dioxide (E 171); iron oxide red (E 172) (only for 25, 100, 150, 200, and 250 mg); iron oxide yellow (E 172) (only for 25, 100, and 200 mg); iron oxide black (E 172) (only for 25, 100, 150, 200, and 250 mg).

What BINATTA looks like and contents of the pack

BINATTA, 25 mg: brownish, biconvex, prolonged-release tablets, oblong in shape (6 mm x 12 mm) with a dividing line on both sides.
The tablet can be divided into equal doses.
BINATTA, 50 mg: white, biconvex, prolonged-release tablets, oblong in shape (6 mm x 13 mm) with a dividing line on both sides.
The tablet can be divided into equal doses.
BINATTA, 100 mg: yellowish, biconvex, prolonged-release tablets, oblong in shape (7 mm x 14 mm) with a dividing line on both sides.
The tablet can be divided into equal doses.
BINATTA, 150 mg: light red, biconvex, prolonged-release tablets, oblong in shape (7 mm x 15 mm) with a dividing line on both sides.
The tablet can be divided into equal doses.
BINATTA, 200 mg: yellow, biconvex, prolonged-release tablets, oblong in shape (8 mm x 16 mm) with a dividing line on both sides.
The tablet can be divided into equal doses.
BINATTA, 250 mg: reddish-brown, biconvex, prolonged-release tablets, oblong in shape (9 mm x 18 mm) with a dividing line on both sides.
The tablet can be divided into equal doses.
BINATTA is available in packs of:
BINATTA, 25 mg
20x1, 30x1, 40x1, 50x1, 54x1, 60x1, or 100x1 prolonged-release tablets in child-resistant, perforated blister packs..
BINATTA, 50–250 mg
20x1, 24x1, 30x1, 50x1, 54x1, 60x1, or 100x1 prolonged-release tablets in child-resistant, perforated blister packs
Not all pack sizes may be marketed.

Marketing authorization holder and manufacturer/importer

Marketing authorization holder:
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel
Germany
Manufacturer/importer:
Develco Pharma GmbH
Grienmatt 27
Farhnau
79650 Schopfheim
Germany
STADA Arzneimittel AG
Stadastrasse 2 – 18
61118 Bad Vilbel
Germany
Centrafarm Services B.V.
Van de Reijtstraat 31-E
4814 NE Breda
Netherlands
To obtain more detailed information on this medicine, contact the representative of the marketing authorization holder:
Stada Pharm sp. z o.o.
ul. Krakowiaków 44
02-255 Warsaw
Phone: +48 22 737 79 20

This medicinal product is authorized in the Member States of the European Economic Area under the following names:

Germany
Tapentadol AL 25 mg Retardtabletten
Tapentadol AL 50 mg Retardtabletten
Tapentadol AL 100 mg Retardtabletten
Tapentadol AL 150 mg Retardtabletten
Tapentadol AL 200 mg Retardtabletten
Tapentadol AL 250 mg Retardtabletten
Croatia
TAPISTA
Czech Republic
Taxemba
Denmark
Tapentadol STADA
Iceland
Tapentadol STADA 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg; forðahylki
Italy
Mudol
Netherlands
Tapentadol retard CF 25 mg, tabletten met verlengde afgifte
Tapentadol retard CF 50 mg, tabletten met verlengde afgifte
Tapentadol retard CF 100 mg, tabletten met verlengde afgifte
Tapentadol retard CF 150 mg, tabletten met verlengde afgifte
Tapentadol retard CF 200 mg, tabletten met verlengde afgifte
Tapentadol retard CF 250 mg, tabletten met verlengde afgifte
Norway
Tapentadol STADA
Poland
BINATTA
Slovakia
Tapestad retard 50 mg, 100 mg, 150 mg, 200 mg, 250 mg
Spain
Tapentadol retard STADA 25 mg comprimidos de liberación prolongada EFG
Tapentadol retard STADA 50 mg comprimidos de liberación prolongada EFG
Tapentadol retard STADA 100 mg comprimidos de liberación prolongada EFG
Tapentadol retard STADA 150 mg comprimidos de liberación prolongada EFG
Tapentadol retard STADA 200 mg comprimidos de liberación prolongada EFG
Tapentadol retard STADA 250 mg comprimidos de liberación prolongada EFG
Sweden
Tapentadol Depot STADA 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg; depottabletter

Date of last revision of the leaflet: